Cardiotoxicity assessment after different adjuvant hypofractionated radiotherapy concurrently associated with trastuzumab in early breast cancer

Elisabetta Bonzano, Marina Guenzi, Renzo Corvò

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To evaluate cardiotoxicity in patients with human epidermal growth factor receptor 2+ (HER2+) breast cancer (29 left-sided, 23 right-sided) treated with adjuvant whole-breast hypofractionated radiotherapy (HRT) concurrently administered with the humanized monoclonal antibody to HER2, trastuzumab. Patients and Methods: From February 2008 to June 2017, 52 patients received three-dimensional conformal RT, with different HRT schemes. Echocardiogram monitoring was used to evaluate the decrease in left ventricular ejection fraction (LVEF). Results: At a median follow-up of 5 years, cardiotoxicity was as follows: among the 15 patients treated with 46 Gy: grade (G) 2 in two (13%), G1 in three (20%), and G0 in 10 (67%);in those treated with 39 Gy (16 patients): G1 in five (31%), and G0 in 11 (69%);among the 21 patients treated with 35 Gy: G2 in one (5%), G1 in five (24%), and G0 in 15 (71%). Conclusion: Trastuzumab was shown to be a safe adjuvant treatment when administered with concomitant HRT since it did not increase cardiotoxicity in those with left-sided breast cancer. No differences in LVEF were observed between the HRT schemes.

Original languageEnglish
Pages (from-to)879-882
Number of pages4
JournalIn Vivo
Volume32
Issue number4
DOIs
Publication statusPublished - Jul 1 2018

Keywords

  • Adjuvant treatment
  • Breast cancer cardiotoxicity
  • Hypofractionated radiotherapy (HRT)
  • Trastuzumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint

Dive into the research topics of 'Cardiotoxicity assessment after different adjuvant hypofractionated radiotherapy concurrently associated with trastuzumab in early breast cancer'. Together they form a unique fingerprint.

Cite this